Now in its 14th Year, SMi's 2012 Superbugs and Superdrugs Conference promises to better than ever before...



About the conference

With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important. This year's conference will consist of a variety of different case study focused presentations featuring real life success stories and failures enabling attendees to learn from and discuss with key industry professionals on challenges facing this rapidly-evolving field.

Senior industry executives in the field will present on their experiences of antibiotic resistance and development of new antibacterial agents.

Key areas to be discussed in this year's conference are:

• Therapies to overcome microbial resistance
• Antimicrobial resistant pathogens
• Gram Positive and Gram Negative bacteria infection treatments
• Cell division inhibitors
• Microbiomes as basic defence mechanisms
• Antibody based strategies
• Regulatory requirements for new antimicrobials
• Government incentive schemes 


Interested in speaking at the conference?  Contact the Conference Producer.

For sponsorship and exhibition opportunities, Contact our Sponsorship Department






Speakers for this year's event include:

Ron Gladue, Research Fellow, Pfizer

Lynn Miesel, Senior Research Fellow, Merck

Neil Ryder, Executive Director, Microbial Vaccines, Novartis

Chris Longshaw, Associate Director of Microbiology, Astellas

Sheo Singh, Senior Investigator, Merck

Mick Gwynn, Director, Microbiology & Infectious Diseases, GlaxoSmithKline

Markus Heep, Principal Medical Scientific Expert, Novartis

Amita Joshi, Sr Research Immunologist, Microbial Vaccines, Merck

Justin Montgomery, Senior Principal Scientist, Pfizer

Bret Sellman, Principal Scientist, Medimmune

Richard Bax, Senior Partner, Transcrip Partners

Christian Felter, Associate Director, Medical Affairs, Astellas

Alice Erwin, Research Fellow, Antibacterial Drug Discovery, Vertex Pharmaceuticals

Neil Woodford, Acting Director, Health Protection Agency

Malcolm Page, Head of Biology, Basilea Pharmaceutica

Barry Hafkin, CMO, Affininum Pharmaceuticals

Lloyd Payne, CEO, Euprotec

Barry Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals

Anthony Coates, Professor of Medical Microbiology, St George's University London

Guy Thwaites,

Reader & Honorary Consultant, Infectious Diseases,KCL/Guy's & St Thomas' Hospitals





Who should attend this event?

Organisations represented at our previous Superbugs and Superdrugs conferences include:


Delegates at our 2011 Superbugs & Superdrugs Conference came from across the world... Join the wide range of high-level delegates at our event in 2012..

  • Pfizer
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Novartis
  • Boehringer-Ingelheim
  • AstraZeneca
  • Merck
  • Vertex
  • Boehringer-Ingelheim
  • Queen Mary University London
  • University of Oxford
  • Basilea Pharmaceuticals
  • Affinium Pharmaceuticals
  • Novexel
  • Quotient Bioresearch
  • TranScrip Partners
  • University of Leeds
  • Rib-X Pharmaceuticals
  • European Commission
  • Kenta Biotech
  • PolyMedix
  • Theravance Cubix


Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 Anti-bacterials; past, present and future

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

  • Past success stories and how to learn from them
  • The current state of developments in anti-bacterial advances
  • Where industry are standing, and future plans for anti-bacterial development
  • Predicting obstacles and plans to overcome them
  • 9:45 Multidrug Resistant Bacteria- Where do we stand?

    Neil Woodford

    Neil Woodford, Acting Director, Health Protection Agency

  • MDR Bacteria related to hospital infections
  • Detecting resistance earlier, and strategies to counter resistance
  • Recent success stories/failures and what can we learn from past experiences
  • 10:20 Morning Coffee

    10:50 Generation of new antibacterial lead molecules: an approach to develop combination therapies for MRSA infections

    Lynn Miesel

    Lynn Miesel, Biology Collaboration Lead, Merck Research Laboratories

  • Whole cell screen to identify b-lactam synergists
  • Methods to define the cellular target of novel antibacterials
  • New b-lactam synergy targets
  • 11:25 Advances in development of AFN-1252, a specific-spectrum, anti-staphylococcal agent

    Barry Hafkin

    Barry Hafkin, CMO, Affinium Pharmaceuticals

  • Review the novel mechanism of action for this new class of drugs, and provide recent in vitro date validating the FabI target for Staphylococcus spp.
  • Present recent in vitro, in vivo animal and human clinical data supporting the progression of AFN-1252 into Phase 2 trials
  • Discuss the potential role for a new anti-Staphyloccocal agent in medical practice
  • 12:00 Targeting Multidrug Resistant Bugs: The Pivotal Role of Preclinical Efficacy Models in Drug Discovery

  • Overview of preclinical  models for efficacy  determination.
  • Emerging resistance and novel approaches to efficacy modelling.
  • Preclinical PKPD modelling as an aid to design of clinical trials
  • Lloyd Payne

    Lloyd Payne, Chief Executive Officer, Euprotec

    Peter Warn

    Peter Warn, Director, Euprotec

    12:40 Networking Lunch

    13:40 Chemical genetic profiling and discovery of Kibdelomycin, a potent new class of bacterial Type II Topoisomerase Inhibitor

    Sheo Singh

    Sheo Singh, Distinguished Senior Investigator, Merck Research Lab

  • Chemical genetic profiling of natural products accelerates antibiotic discovery
  • Identification of a new class of antibiotics from a new member of Kibdelosporangium
  • Kibdelomycin exhibits broad spectrum gram positive antibacterial activity
  • Kibdelomycin is a potent inhibitor of bacterial type-II topoisomerases
  • 14:15 Safe drugs for bad bugs – EV-035, a new topoisomerase inhibitor

    Jutta Heim

    Jutta Heim, Professor of Biotechnology, Chief Scientific Officer, Evolva SA

    • Novel 2-pyridones
    • Broad-spectrum and very potent
    • Active on MDR pathogens, including quinolone resistance
    • Favourable PK and Tox profile
    • Active in in vivo models

    14:55 Antibacterial developments in Tuberculosis research

    Anthony Coates

    Anthony Coates, Professor, St George Hospital Medical School

  • New models are needed for anti-bacterial development in TB
  • Novel in vitro models which mimic TB persister bacteria
  • Considering a new murine model which is more similar to human tuberculosis than current models
  • 15:30 Tuberculosis treatment failure: bad bugs of bad drugs?

    Guy Thwaites

    Guy Thwaites, Visiting Research, Imperial College London

  • When does TB treatment fail?
  • Do M. Tuberculosis ‘superbugs’ exist?
  • Does bacterial genetic variation influence disease phenotype and response to treatment?
  • Or are our drugs inadequate?
  • 16:05 Afternoon Tea

    16:35 Assessing the FDA's Objective Endpoints and Clinical Test of Cure: Results from a Phase 2B ABSSSI Study Comparing Delafloxacin with Vancomycin and Zyvox

    Jarrod Longcor

    Jarrod Longcor, Director Business Development, Rib-X Pharmaceuticals

  • Delafloxacin is a unique fluoroquinolone, with broad-spectrum activity, including MRSA, demonstration of efficacy in 4 Phase 2 clinical trials and a strong safety profile in nearly 1400 patients
  • Delafloxacin shows a statistically significant difference in rates of efficacy in the Phase 2B trial when compared with vancomycin
  • Delafloxacin shows not only lesion-spread cessation in the 48 - 72 hour window but also substantial lesion reduction in the same timeframe
  • Delafloxacin is efficacious across lesion types, including major abscesses, cellulitis, wounds and burns, in a population with mean and median lesion sizes larger than seen in historical trials
  • 17:15 Novel antibacterial development for multidrug resistant bugs

    Chris Longshaw

    Chris Longshaw, Associate Director, Microbiology, Astellas Pharma Europe

  • Current treatment options for Clostridium difficile infection
  • Fidaxomicin: a new treatment paradigm?
  • An overview of other CDI therapies in development
  • 17:45 Multi-resistant bacteria case study: C. Diff

    Christian Felter

    Christian Felter, Associate Director, Medical Affairs, Astellas Pharma Europe

  • The spectrum of C. Diff infections and their effects on patients
  • Guidelines outlined by the HICPAC
  • How and why transmissions occur in healthcare facilities
  • 18:15 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Ronald Gladue

    Ronald Gladue, Research Fellow, Pfizer Global Biotherapeutics Technologies

    9:10 Development of vaccines for the prevention of antibiotic-resistant bacterial infections

    Amita Joshi

    Amita Joshi, Sr Research Immunologist, Merck Research Laboratories

  • Focus on Staphylococcus aureus
  • Identifying vaccine targets through rational design
  • Preclinical data: towards a changing paradigm for protection
  • 9:45 Fungal Infection; trends and progress in novel therapies

    Neil Ryder

    Neil Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.

  • Emerging fungal pathogens and the need for new drugs
  • Trends in antifungal drug resistance
  • Recent developments in novel antifungal therapies
  • Targeted approached: do they (can they) work?
  • 10:20 Morning Coffee

    10:50 Antibody based therapies for the treatment and prevention of bacterial infections

    Ronald Gladue

    Ronald Gladue, Research Fellow, Pfizer Global Biotherapeutics Technologies

  • Rationale and desired characteristics
  • Strategy and preclinical date
  • Focus on gram negative infections
  • 11:25 Exploiting Novel Bacterial Topoisomerase Inhibitors (NBTIs) with public-private partnerships

    Michael Gwynn

    Michael Gwynn, Director, Microbiology, Infectious Diseases CEDD, GlaxoSmithKline

    • Brief pipeline review
    • Structure based exploitation of DNA gyrase
    • Importance of public-private partnerships

    12:00 Can target-based projects discover novel gram-negative antibiotics? LpxX as an example

    Alice Erwin

    Alice Erwin, Research Fellow, Antibacterial Drug Discovery, Vertex Pharmaceuticals Inc

  • Critical issues in discovery of novel classes of Gram-negative antibiotics
  • History of LpxC as a target illustrates the successes and the problems
  • Cell-based pathway screen led to first generation of LpxC inhibitors (Merck)
  • Later projects: broader spectrum and efficacy in animals
  • No clinical candidates - yet
  • 12:35 Networking Lunch

    13:35 Novel LpxC inhibitors for treatment of gram-negative infections

    Justin Montgomery

    Justin Montgomery, Senior Principal Scientist, Pfizer Antibacterials RU

  • The SAR of a new series of LpxC inhibitors
  • PK and strategies to lower human dose projections
  • X-ray crystallographic analysis of bound inhibitors
  • MIC90s for multiple Gram-Negatives
  • 14:10 Modifications of beta-lactams to meet the challenge of bacterial resistance

    Malcolm Page

    Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd

  • Beta-lactam resistance in Gram-positive and Gram-Negative bacteria
  • Anti-MRSA cephalosporins
  • Siderophore beta-lactams - circumventing the Gram-Negative permeability barrier
  • Engineering beta-lactamase stability in cephems
  • 14:45 The antibiotic pipeline: where is it and what needs fixing?

    Barry I Eisenstein

    Barry I Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals

  • The unique public health threat posed by growing bacterial resistance to antibiotics
  • The present challenges of the R&D investment model for antibacterials
  • The associated public policy imperatives
  • Potential government-driven solutions to fix this 'market failure'
  • Discussion into the current work carried out by the PhRMA committee on emerging pathogens
  • 15:25 Afternoon Tea

    15:55 ‘Almost there?’ – The challenges of late-phase antibiotic development

    Markus Heep

    Markus Heep, Principal Medical Scientific Expert, Novartis Pharma GmbH

  • Focus on the most frequent phase III indications
  • Systemic treatment of gram-positive or mixed infections
  • Skin infections and Pneumonia


  • 16:30 The EU research strategy to combat antimicrobial resistance

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

  • Review of the Commission's action plan against the rising threats from antimicrobial resistance
  • Discussion into the effects of the plan, launched November 2011
  • Evaluating current and future research activites
  • 17:05 Antibacterial developments in South East Asia

    Stephen  Baker

    Stephen Baker, Microbiologist, Oxford University Clinical Research Unit

  • Antibacterials in emerging markets
  • The role of public funding in anti-infective research and development
  • Research and development tax incentives
  • 17:40 Chairman’s Closing Remarks and Close of Day Two



    Copthorne Tara Hotel

    Scarsdale Place
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out